Latest Entrant To UK Early Access Scheme Is AstraZeneca's Osimertinib
This article was originally published in The Pink Sheet Daily
Executive Summary
Lung cancer drug, recently approved in the US as Tagrisso, is fourth product made available early to UK patients as it awaits EU marketing approval.